Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $25.00 at BMO Capital Markets

Silence Therapeutics (NASDAQ:SLN - Free Report) had its price objective cut by BMO Capital Markets from $67.00 to $25.00 in a research report released on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

Several other research firms have also recently commented on SLN. William Blair restated an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, January 29th. Chardan Capital restated a "buy" rating and issued a $55.00 target price on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Finally, The Goldman Sachs Group cut their target price on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $40.67.

Silence Therapeutics Stock Up 2.3 %

Shares of SLN traded up $0.11 on Tuesday, hitting $4.85. The company's stock had a trading volume of 197,333 shares, compared to its average volume of 307,544. The firm has a market capitalization of $145.16 million, a price-to-earnings ratio of -3.09 and a beta of 1.08. The firm's fifty day moving average price is $5.40 and its 200-day moving average price is $11.37. Silence Therapeutics has a fifty-two week low of $4.06 and a fifty-two week high of $27.72.

Remove Ads

Institutional Investors Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC raised its stake in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after acquiring an additional 2,793 shares during the period. JPMorgan Chase & Co. bought a new stake in Silence Therapeutics in the 4th quarter valued at $26,000. Y Intercept Hong Kong Ltd raised its stake in Silence Therapeutics by 22.9% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company's stock valued at $383,000 after acquiring an additional 3,923 shares during the period. GAMMA Investing LLC raised its stake in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after acquiring an additional 5,233 shares during the period. Finally, Virtus ETF Advisers LLC raised its stake in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after acquiring an additional 6,098 shares during the period. Institutional investors own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.